134 related articles for article (PubMed ID: 19341717)
1. Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
Blanchet B; Saboureau C; Benichou AS; Billemont B; Taieb F; Ropert S; Dauphin A; Goldwasser F; Tod M
Clin Chim Acta; 2009 Jun; 404(2):134-9. PubMed ID: 19341717
[TBL] [Abstract][Full Text] [Related]
2. An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.
Zhen Y; Thomas-Schoemann A; Sakji L; Boudou-Rouquette P; Dupin N; Mortier L; Vidal M; Goldwasser F; Blanchet B
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jun; 928():93-7. PubMed ID: 23602929
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry.
Qiu F; Bian W; Li J; Ge Z
Biomed Chromatogr; 2013 May; 27(5):615-21. PubMed ID: 23108983
[TBL] [Abstract][Full Text] [Related]
4. A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.
Faivre L; Gomo C; Mir O; Taieb F; Schoemann-Thomas A; Ropert S; Vidal M; Dusser D; Dauphin A; Goldwasser F; Blanchet B
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2345-50. PubMed ID: 21737360
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Rais R; Zhao M; He P; Xu L; Deeken JF; Rudek MA
Biomed Chromatogr; 2012 Nov; 26(11):1315-24. PubMed ID: 22259028
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
7. A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.
Etienne-Grimaldi MC; Renée N; Izzedine H; Milano G
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(29):3757-61. PubMed ID: 19797000
[TBL] [Abstract][Full Text] [Related]
8. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a high-performance liquid chromatography ultraviolet method for lapatinib quantification in human plasma.
Escudero-Ortiz V; Pérez-Ruixo JJ; Valenzuela B
Ther Drug Monit; 2013 Dec; 35(6):796-802. PubMed ID: 23942544
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice.
Escudero-Ortiz V; Pérez-Ruixo JJ; Valenzuela B
Ther Drug Monit; 2015 Apr; 37(2):172-9. PubMed ID: 25072946
[TBL] [Abstract][Full Text] [Related]
11. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.
Haznedar JO; Patyna S; Bello CL; Peng GW; Speed W; Yu X; Zhang Q; Sukbuntherng J; Sweeny DJ; Antonian L; Wu EY
Cancer Chemother Pharmacol; 2009 Sep; 64(4):691-706. PubMed ID: 19169880
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice.
Escudero-Ortiz V; Pérez-Ruixo JJ; Valenzuela B
Ther Drug Monit; 2014 Jun; 36(3):317-25. PubMed ID: 24365980
[TBL] [Abstract][Full Text] [Related]
13. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Minkin P; Zhao M; Chen Z; Ouwerkerk J; Gelderblom H; Baker SD
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Oct; 874(1-2):84-8. PubMed ID: 18823825
[TBL] [Abstract][Full Text] [Related]
14. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.
de Bruijn P; Sleijfer S; Lam MH; Mathijssen RH; Wiemer EA; Loos WJ
J Pharm Biomed Anal; 2010 Mar; 51(4):934-41. PubMed ID: 19931354
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Szałek E; Karbownik A; Grabowski T; Sobańska K; Wolc A; Grześkowiak E
Pharmacol Rep; 2013; 65(5):1383-90. PubMed ID: 24399735
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples.
Velpandian T; Mathur R; Agarwal NK; Arora B; Kumar L; Gupta SK
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 May; 804(2):431-4. PubMed ID: 15081939
[TBL] [Abstract][Full Text] [Related]
17. Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma.
Moreno JM; Wojnicz A; Steegman JL; Cano-Abad MF; Ruiz-Nuño A
Biomed Chromatogr; 2013 Apr; 27(4):502-8. PubMed ID: 23034891
[TBL] [Abstract][Full Text] [Related]
18. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice.
Blanchet B; Billemont B; Cramard J; Benichou AS; Chhun S; Harcouet L; Ropert S; Dauphin A; Goldwasser F; Tod M
J Pharm Biomed Anal; 2009 May; 49(4):1109-14. PubMed ID: 19278805
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
Lankheet NA; Kloth JS; Gadellaa-van Hooijdonk CG; Cirkel GA; Mathijssen RH; Lolkema MP; Schellens JH; Voest EE; Sleijfer S; de Jonge MJ; Haanen JB; Beijnen JH; Huitema AD; Steeghs N
Br J Cancer; 2014 May; 110(10):2441-9. PubMed ID: 24736581
[TBL] [Abstract][Full Text] [Related]
20. Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study.
Gurav SD; Gilibili RR; Jeniffer S; Giri S; Srinivas NR; Mullangi R
Biomed Chromatogr; 2011 Jul; 25(7):794-800. PubMed ID: 20872957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
